The University of Pittsburgh Multicenter AIDS Cohort Study (Pitt MACS) Clinical Research Site (CRS) was established in 1983 by Dr. C. Rinaldo, PI, as one of 4 MACS CRS as a prospective cohort study of the natural history of HIV infection and the impact of effective combination antiretroviral therapies (cART) in men who have sex with men (MSM). We will continue to combine genetic, virologic, immunologic and psychosocial approaches and utilize the specimen cryorepository for long-term characterization of Pitt MACS participants. Along with our new satellite clinic site at The Ohio State University (OSU) led by Dr. S. Koletar, we will continue follow-up of the cohort with a dynamic enrollment to enable further elucidation of the biology and response to HIV infection, and distinguishing the effects of age, HIV, evolving cART regimens, genetics, co- infections and behavior use on clinical outcomes and causally-associated biomarkers. This is a transition to a rolling cohort design to replace existing cohort members who die or otherwise are permanently lost to follow-up. The Pitt MACS scientific agenda focuses on clinical epidemiology, pathogenesis, psychosocial factors, and development of novel methods for the study of HIV disease. The Pitt MACS is ideally positioned to address these issues because of long-term standardized follow-up, an extensive repository and an appropriate control group of HIV-uninfected MSM with similar lifestyles, behaviors, and demographics. The Pitt MACS contributes strength and innovation in three areas: (a) studies of viral genomics and host immunopathogenesis including HHV-8/KSHV and HCV coinfections and regulation by host microRNAs, (b) in depth analysis of effects of HIV infection in the brain and lungs including microbiome analysis, and (c) studies of syndemics and resiliencies in aging MSM including effects on depression, substance use and sexual behavior. The Pitt MACS CRS will continue to contribute via the MACS Executive Committee and Working Groups with expertise in all aspects of HIV infection to successfully address our 7 scientific aims that are identical to those in Part A. The Pitt MACS will continue to characterize the long-term, natural and treated history of HIV infection in MSM, provide insight into the clinical epidemiology of HIV, and further our understanding of predictors of disease among HIV positive MSM.

Public Health Relevance

The scientific leadership and methods implemented by the Pitt MACS will enable the MACS to answer important questions relevant to treated HIV-infected MSM, the group with the highest HIV incidence in the US, and questions about the interaction of HIV and aging, important as the HIV-infected population shifts into older ages. The proposed research will provide information for development and administration of new interventions for HIV, as well as for the prevention of AIDS-defining and non-AIDS defining outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI035041-25
Application #
9265768
Study Section
Special Emphasis Panel (ZAI1-NLE-A (J1))
Program Officer
Roe, Joanad'Arc C
Project Start
1993-04-01
Project End
2019-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
25
Fiscal Year
2017
Total Cost
$3,335,825
Indirect Cost
$1,042,453
Name
University of Pittsburgh
Department
Public Health & Prev Medicine
Type
Other Domestic Higher Education
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Lake, Jordan E; Li, Xiuhong; Palella Jr, Frank J et al. (2018) Metabolic health across the BMI spectrum in HIV-infected and HIV-uninfected men. AIDS 32:49-57
Ascher, Simon B; Scherzer, Rebecca; Estrella, Michelle M et al. (2018) Association of Urinary Biomarkers of Kidney Injury with Estimated GFR Decline in HIV-Infected Individuals following Tenofovir Disoproxil Fumarate Initiation. Clin J Am Soc Nephrol 13:1321-1329
Hanna, David B; Moon, Jee-Young; Haberlen, Sabina A et al. (2018) Carotid artery atherosclerosis is associated with mortality in HIV-positive women and men. AIDS 32:2393-2403
Levine, Andrew J; Martin, Eileen; Munro, Cynthia A et al. (2018) Intraindividual variability in neurocognitive performance: No influence due to HIV status or self-reported effort. J Clin Exp Neuropsychol 40:1044-1049
Robbins, Hilary A; Wiley, Dorothy J; Ho, Ken et al. (2018) Patterns of repeated anal cytology results among HIV-positive and HIV-negative men who have sex with men. Papillomavirus Res 5:143-149
Abraham, Alison G; Zhang, Long; Calkins, Keri et al. (2018) Vitamin D status and immune function reconstitution in HIV-infected men initiating therapy. AIDS 32:1069-1076
Price, Jennifer C; Seaberg, Eric C; Stosor, Valentina et al. (2018) Aspartate aminotransferase-to-platelet ratio index increases significantly 3 years prior to liver-related death in HIV-hepatitis-coinfected men. AIDS 32:2636-2638
Halec, Gordana; Waterboer, Tim; Brenner, Nicole et al. (2018) Serological Assessment of 18 Pathogens and Risk for AIDS-associated Non-Hodgkin Lymphoma. J Acquir Immune Defic Syndr :
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Wu, Minjie; Fatukasi, Omalara; Yang, Shaolin et al. (2018) HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition. AIDS 32:1803-1810

Showing the most recent 10 out of 552 publications